VXRT - NASDAQ
Vaxart, Inc.
$0.60
+0.083%Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
At a Glance
Live SnapshotVaxart, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Vaxart, Inc. Income Statement
VXRT • NASDAQ
| Vaxart, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
237.3M | 28.7M | 7.4M | 107K | 892K | 4M | 9.9M | 4.2M | 5.8M | 8.9M | 9.3M | 24.6M | 68.7M | 33.6M | 14.8M | 35M | 10.5M | 0.0 | 0.0 | 89.9M | |
GROSS PROFIT | ||||||||||||||||||||
(0.0) | (0.0) | (4.5M) | (0.0) | (48.7M) | (19.9M) | (14.5M) | (17.3M) | (12.4M) | (17.6M) | (100K) | (3.6M) | (51.1M) | (19.7M) | (1.5M) | (4M) | (2M) | (0.0) | (0.0) | (62.7M) | |
237.3M | 28.7M | 2.9M | 107K | -47.9M | -15.8M | -4.7M | -13.1M | -6.5M | -8.7M | 9.2M | 21M | 17.6M | 13.9M | 13.4M | 31.1M | 8.5M | 0.0 | 0.0 | 27.2M | |
OPERATING INCOME | ||||||||||||||||||||
(219.2M) | (95M) | (86.2M) | (114.7M) | (24.9M) | (14.4M) | (20.7M) | (24M) | (83K) | (36.3M) | (34.3M) | (29.2M) | (27.7M) | (33.5M) | (23.1M) | (32.3M) | (26.5M) | (25M) | (44.9M) | (61.3M) | |
(17.6M) | (20.8M) | (22.6M) | (29.4M) | (21.9M) | (15.2M) | (6.2M) | (6.7M) | (2.6M) | (5.7M) | (5.6M) | (6.6M) | (6.9M) | (13.6M) | (5.4M) | (6.2M) | (10M) | (12.4M) | (26.1M) | (32.6M) | |
(201.6M) | (74.2M) | (68.1M) | (81.1M) | (48.7M) | (19.9M) | (14.5M) | (17.3M) | (12.4M) | (28.3M) | (26.3M) | (19.8M) | (17.5M) | (15.5M) | (17.8M) | (26.1M) | (16.5M) | (12.6M) | (18.8M) | (28.7M) | |
18.1M | -66.3M | -83.3M | -114.6M | -72.8M | -30.2M | -15.8M | -21.8M | -9.1M | -27.5M | -25.2M | -19.5M | -11.5M | -22.1M | -9.8M | -1.2M | -18M | -25M | -44.9M | -61.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(2.8M) | (3M) | (1.4M) | (1.3M) | (1.5M) | (1.9M) | (2.4M) | (2.7M) | (0.0) | (1.8M) | (300K) | (0.0) | (0.0) | (0.0) | (0.0) | (210K) | (1.1M) | (3.9M) | (3.5M) | (3.7M) | |
-1.2M | -426K | 1.2M | -58K | -1.4M | -1.8M | -2.2M | -2.6M | 0.0 | -1.8M | -300K | 0.0 | 200K | 1.3M | 194K | 20K | -703K | 677K | 2.6M | 424K | |
(0.0) | (0.0) | -4.5M | (4.3M) | -45.7M | -20.7M | (0.0) | (0.0) | (0.0) | (200K) | (100K) | (300K) | (200K) | (1.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.3M | -395K | 1.1M | 6.9M | 2.4M | -1.8M | -2.4M | 3.9M | -467K | -1.7M | -200K | 300K | 200K | 13.3M | -2M | 311K | -751K | -777K | 6.1M | 7.4M | |
16.8M | -66.7M | -82.2M | -107.7M | -70.4M | -32M | -18.2M | -17.9M | -9.6M | -29.1M | -25.4M | -19.2M | -11.3M | -8.8M | -9.5M | -887K | -18.7M | -25.7M | -38.8M | -60.7M | |
NET INCOME | ||||||||||||||||||||
(476K) | (260K) | (261K) | (67K) | (107K) | (238K) | (490K) | (109K) | (0.0) | (300K) | (0.0) | -100K | -300K | (100K) | -2M | -1.8M | (0.0) | -2.8M | -14.3M | -753K | |
16.3M | -66.9M | -82.5M | -107.8M | -70.5M | -32.2M | -18.6M | -18M | -12.5M | -29.4M | -25.4M | -19.1M | -11M | -8.9M | -4.5M | 878K | -18.7M | -18.7M | 47.1M | -58.7M |
SEC Filings
VXRT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
S-1/A S-1/A (Amended) N/A | May 18, 2026 | May 18, 2026 | ||
S-1 S-1 N/A | May 08, 2026 | May 08, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
S-3 S-3 N/A | April 16, 2026 | April 16, 2026 |
Related Guides
Continue your VXRT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.